TABLE 2. Symptoms and limitations present during the follow-up of COVID-19 survivors 2, 6, and 12 months after hospital discharge from Hospital Universitário Clementino Fraga Filho.
|
Variable |
2-month assessment n = 88 |
6-month assessment n = 77 |
12-month assessment n = 88 |
|---|---|---|---|
|
Time from discharge to visit, days Median (IQR) |
72 (59–88) |
199 (187–213) |
369 (354–390) |
|
Symptoms, n (%) |
|
|
|
|
Dyspnea |
48 (54.5%) |
39 (44.3%) |
29 (33.0%) |
|
Fatigue |
44 (50.0%) |
34 (44.2%) |
28 (31.8%) |
|
Myalgia |
41 (46.6%) |
28 (36.4%) |
31 (35.2%) |
|
Muscle weakness |
41 (46.6%) |
28 (36.4%) |
25 (28.4%) |
|
Arthralgia |
41 (46.6%) |
34 (44.2%) |
41 (46.6%) |
|
Anxiety |
41 (46.6%) |
42 (55.3%) |
42 (47.7%) |
|
Chest pain |
28 (31.8%) |
22 (28.6%) |
22 (25.0%) |
|
Headache |
27 (30.7%) |
23 (29.9%) |
27 (30.7%) |
|
Cough |
22 (25.0%) |
23 (29.9%) |
31 (35.2%) |
|
Limitations in daily activities, n (%) |
|
|
|
|
No limitation |
27 (30.7%) |
38 (50.0%) |
50 (56.8%) |
|
Limitation |
61 (69.3%) |
38 (50.0%) |
38 (43.2%) |
|
Returned to work, n (%)a |
|
|
|
|
Yes |
23 (65.7%) |
19 (73.1%) |
28 (82.4%) |
|
No |
12 (34.3%) |
7 (26.9%) |
6 (17.6%) |
Notes: mMRC, modified Medical Research Council score.
Data are related to patients that worked before COVID-19.
Source: Prepared by the authors using the study results.